Sodium glucose transporter 2 inhibitor exposure and the risk of congenital malformations: nationwide birth cohort study

In this study, SGLT2 inhibitor use during the first trimester was not associated with an increased risk of congenital malformations. Nonetheless, the observed increased risk of congenital heart defects during the organogenesis period highlights the importance of exposure timing and warrants cautious interpretation. These findings provide evidence to guide clinical decision-making regarding antidiabetic medication use during pregnancy.